Importance of TAK-1 levels in patients with non-small cell lung carcinoma
Yıl: 2022 Cilt: 30 Sayı: 4 Sayfa Aralığı: 574 - 583 Metin Dili: İngilizce DOI: 10.5606/tgkdc.dergisi.2022.21975 İndeks Tarihi: 04-05-2023
Importance of TAK-1 levels in patients with non-small cell lung carcinoma
Öz: Background: In this study, we aimed to investigate the relationship between survival, tumor dimension, grade and stage in respect to transforming growth factor-β-activating kinase (TAK-1) extensity, severity and total score in patients undergoing resection for Stage 1B-2B non-small cell lung cancer. Methods: Between January 2000 and December 2014, a total of 70 patients (64 males, 6 females; mean age: 63.4+9.6 years; range, 32 to 78 years) who underwent surgery with resectable non-small cell lung cancer in Stage 1-2b were included. The patients were divided into two groups as Group 1 (n=35) consisting of patients with squamous cell carcinoma and Group 2 (n=35) consisting of patients with adenocarcinoma. The control group consisted of 20 patients (Group 3) who underwent surgery due to non-cancer causes. The relationship between TAK-1 staining (extensity, severity, total scores) and grade, survival time, T factor, N factor, and chemotherapy administration was examined. Pathology specimens of the patients were evaluated for the degree of staining with TAK-1 primary antibody. Results: There was a strong correlation between the tumor grade and TAK-1 primary antibody staining level, independently from histopathological type. A significant correlation was found between dimension, stage, and TAK-1 staining in patients with squamous cell carcinoma. No statistically significant difference was found in the other factors, except for grade factor, in patients with adenocarcinoma. Conclusion: The current study provides precious information about the effects of TAK-1, in clinicopathological behavior and survival of malignant cells, particularly in common histopathological types of lung cancer. We believe that our data can be useful, particularly in evaluating the response to targeted therapies and the prognosis of the disease.
Anahtar Kelime: Küçük hücre dışı akciğer kanserli hastalarda TAK-1 düzeylerinin önemi
Öz: Amaç: Bu çalışmada, Evre 1B-2B küçük hücreli dışı akciğer kanseri nedeniyle rezeksiyon yapılan hastalarda dönüştürücü büyüme faktörü-beta aktive edici kinaz (TAK-1) yaygınlığı, şiddeti ve total skoru açısından sağkalım, tümör boyutu, gradı ve evresi arasındaki ilişki incelendi. Çalışma planı: Ocak 2000 - Aralık 2014 tarihleri arasında Evre 1-2b rezektabl küçük hücreli dışı akciğer kanseri nedeniyle ameliyat edilen toplam 70 hasta (64 erkek, 6 kadın; ort. yaş: 63.4+9.6 yıl; dağılım, 32-78 yıl) çalışmaya alındı. Hastalar, skuamöz hücreli kanserli olanlar Grup 1 (n=35) ve adenokarsinomlu olanlar Grup 2 (n=35) olmak üzere iki gruba ayrıldı. Kontrol grubu (Grup 3), kanser dışı nedenlerle ameliyat edilen 20 hastadan oluşuyordu. TAK-1 boyanma dereceleri, (şiddet, yaygınlık, toplam skor) ile grade, sağkalım süresi, T faktörü, N faktörü ve kemoterapi uygulaması arasındaki ilişki incelendi. Hastaların patoloji örnekleri, TAK-1 primer antikorunun boyanma derecesi açısından değerlendirildi. Bulgular: Histopatolojik tipten bağımsız olarak, tümör gradı ile TAK-1 primer antikoru boyanma düzeyleri arasında güçlü bir ilişki bulundu. Skuamöz hücreli karsinomlu hastalarda tümör boyutu, evresi ve TAK-1 primer antikoru boyanma düzeyleri arasında anlamlı bir ilişki vardı. Adenokarsinomlu hastalarda ise, tümör gradı dışında diğer faktörler arasında istatistiksel olarak anlamlı bir fark saptanmadı. Sonuç: Bu çalışma, TAK-1'in, özellikle yaygın histopatolojik akciğer kanseri tiplerinde, malign hücrelerin klinikopatolojik davranışı ve sağkalımı üzerindeki etkileri hakkında değerli bilgiler vermektedir. Verilerimizin, özellikle hedefe yönelik tedavilere yanıtın ve hastalığın prognozunun değerlendirilmesinde kullanışlı olabileceğini düşünmekteyiz.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e1S-e29S.
- 2. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 2018;21:425-532.
- 3. Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis 2017;20:409-26.
- 4. Taniguchi F, Harada T, Miyakoda H, Iwabe T, Deura I, Tagashira Y, et al. TAK1 activation for cytokine synthesis and proliferation of endometriotic cells. Mol Cell Endocrinol 2009;307:196-204.
- 5. Zhu J, Li Q, He JT, Liu GY. Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance. Int J Clin Exp Pathol 2015;8:15801-7.
- 6. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol 2012;4:128-34.
- 7. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015;10:1243-60.
- 8. Sullu Y, Demirag GG, Yildirim A, Karagoz F, Kandemir B. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathology, Research and Practice 2011;207:747-53.
- 9. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008-11.
- 10. Shirakabe K, Yamaguchi K, Shibuya H, Irie K, Matsuda S, Moriguchi T, et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 1997;272:8141-4.
- 11. Sakurai H, Miyoshi H, Toriumi W, Sugita T. Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation. J Biol Chem 1999;274:10641-8.
- 12. Santoro R, Carbone C, Piro G, Chiao PJ, Melisi D. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. Drug Resist Updat 2017;33- 35:36-42.
- 13. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937s-43s.
- 14. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest 2014;124:3807-24.
- 15. Safina A, Sotomayor P, Limoge M, Morrison C, Bakin AV. TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res 2011;9:1042-53.
- 16. Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C, et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 2011;12:1176-83.
- 17. Cai PC, Shi L, Liu VW, Tang HW, Liu IJ, Leung TH, et al. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget 2014;5:7549-62.
- 18. Carbone C, Melisi D. NF-κB as a target for pancreatic cancer therapy. Expert Opin Ther Targets 2012;16 Suppl 2:S1-10.
- 19. Zhang Y, Mi X, Song Z, Li Y, YingShi, Niu J. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway. Biomed Pharmacother 2018;104:729-37.
- 20. Vucur M, Roderburg C, Bettermann K, Tacke F, Heikenwalder M, Trautwein C, et al. Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma? Oncotarget 2010;1:373-8.
- 21. Lam CR, Tan C, Teo Z, Tay CY, Phua T, Wu YL, et al. Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells. Cell Death Dis 2013;4:e848.
| APA | nahırcı z, bilgin buyukkarabacak y, Sullu Y, basoglu a (2022). Importance of TAK-1 levels in patients with non-small cell lung carcinoma. , 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| Chicago | nahırcı zeynep pelin,bilgin buyukkarabacak yasemin,Sullu Yurdanur,basoglu ahmet Importance of TAK-1 levels in patients with non-small cell lung carcinoma. (2022): 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| MLA | nahırcı zeynep pelin,bilgin buyukkarabacak yasemin,Sullu Yurdanur,basoglu ahmet Importance of TAK-1 levels in patients with non-small cell lung carcinoma. , 2022, ss.574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| AMA | nahırcı z,bilgin buyukkarabacak y,Sullu Y,basoglu a Importance of TAK-1 levels in patients with non-small cell lung carcinoma. . 2022; 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| Vancouver | nahırcı z,bilgin buyukkarabacak y,Sullu Y,basoglu a Importance of TAK-1 levels in patients with non-small cell lung carcinoma. . 2022; 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| IEEE | nahırcı z,bilgin buyukkarabacak y,Sullu Y,basoglu a "Importance of TAK-1 levels in patients with non-small cell lung carcinoma." , ss.574 - 583, 2022. 10.5606/tgkdc.dergisi.2022.21975 |
| ISNAD | nahırcı, zeynep pelin vd. "Importance of TAK-1 levels in patients with non-small cell lung carcinoma". (2022), 574-583. https://doi.org/10.5606/tgkdc.dergisi.2022.21975 |
| APA | nahırcı z, bilgin buyukkarabacak y, Sullu Y, basoglu a (2022). Importance of TAK-1 levels in patients with non-small cell lung carcinoma. Türk Göğüs Kalp Damar Cerrahisi Dergisi, 30(4), 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| Chicago | nahırcı zeynep pelin,bilgin buyukkarabacak yasemin,Sullu Yurdanur,basoglu ahmet Importance of TAK-1 levels in patients with non-small cell lung carcinoma. Türk Göğüs Kalp Damar Cerrahisi Dergisi 30, no.4 (2022): 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| MLA | nahırcı zeynep pelin,bilgin buyukkarabacak yasemin,Sullu Yurdanur,basoglu ahmet Importance of TAK-1 levels in patients with non-small cell lung carcinoma. Türk Göğüs Kalp Damar Cerrahisi Dergisi, vol.30, no.4, 2022, ss.574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| AMA | nahırcı z,bilgin buyukkarabacak y,Sullu Y,basoglu a Importance of TAK-1 levels in patients with non-small cell lung carcinoma. Türk Göğüs Kalp Damar Cerrahisi Dergisi. 2022; 30(4): 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| Vancouver | nahırcı z,bilgin buyukkarabacak y,Sullu Y,basoglu a Importance of TAK-1 levels in patients with non-small cell lung carcinoma. Türk Göğüs Kalp Damar Cerrahisi Dergisi. 2022; 30(4): 574 - 583. 10.5606/tgkdc.dergisi.2022.21975 |
| IEEE | nahırcı z,bilgin buyukkarabacak y,Sullu Y,basoglu a "Importance of TAK-1 levels in patients with non-small cell lung carcinoma." Türk Göğüs Kalp Damar Cerrahisi Dergisi, 30, ss.574 - 583, 2022. 10.5606/tgkdc.dergisi.2022.21975 |
| ISNAD | nahırcı, zeynep pelin vd. "Importance of TAK-1 levels in patients with non-small cell lung carcinoma". Türk Göğüs Kalp Damar Cerrahisi Dergisi 30/4 (2022), 574-583. https://doi.org/10.5606/tgkdc.dergisi.2022.21975 |
